Case File 02 · Thyroid & Metabolic

Thyroid markers, before the prescription

Advised to start levothyroxine, this patient chose eight closely monitored weeks to address the physiological environment around the thyroid first, under supervision, with a clear threshold to start medication if needed.

Patient

47, perimenopausal

Presenting Complaint

Severe fatigue, near bed-bound

Clinical Context

Endocrinologist recommended levothyroxine

History & Presentation

Starting symptoms

Severe fatigue with markedly reduced functional capacity, described as previously near bed-bound. Recurrent binge-eating behavior and food cravings. Perimenopausal symptoms, anxiety and disrupted sleep. Recurrent urinary tract infections and urinary incontinence, alongside chronic cervical and spinal pain and a history of repeated antibiotic and NSAID exposure.

Baseline Markers · Week 0

What the panel showed

Marker	Baseline	Read
TSH	9.2 µIU/mL	Elevated
Free T4	0.53 ng/dL	Low
Free T3	2.92 pg/mL	Monitor
Thyroglobulin antibodies	432.6 IU/mL	Autoimmune
Fasting insulin	13.46 µIU/mL	Elevated
Triglycerides	172.7 mg/dL	Elevated
LDL-C	168 mg/dL	Elevated
ApoB	140 mg/dL	Elevated
Ferritin	23.6 ng/mL	Low
hs-CRP	2.95 mg/L	Monitor
ESR	22 mm/hr	Monitor
DHEAS	37.4 µg/dL	Low

Pattern Identified

Thyroid dysfunction sitting inside a wider network: hyperinsulinemia, dyslipidemia, iron deficiency, systemic inflammation, sleep disruption and perimenopausal hormonal change, each plausibly feeding the others.

Strategic Priority

Repair the environment, on a clear clock

A shared decision was made to undertake a closely monitored, time-limited intervention before pharmacological treatment: restoring protein adequacy and muscle function, regulating glucose, repleting nutritional deficiencies, optimizing gut health, normalizing sleep and stress physiology, supporting hormonal balance, and building physical capacity, all before revisiting the medication decision.

This decision cannot be generalized and requires qualified supervision with clear thresholds for starting therapy.

Implementation · 8 Weeks

What was implemented

Weeks 1-4 · Foundation

Protein toward ~100 g/day, plus creatine
Structured resistance training
Lower glycaemic-load diet with meal restructuring, post-meal movement
Vitamin D, B-vitamins, omega-3s, probiotics, magnesium
Time-limited gluten and lactose elimination trial
Sleep optimization and stress-regulation practices

Weeks 5-8 · Progression

Continued and adjusted metabolic, nutritional and gut interventions
Advanced resistance training
Targeted iron deficiency management
DHEA supplementation and phase-specific progesterone support
Strategies directed at estrogen metabolism

Objective Progress

What moved

Marker	Baseline	Week 8	Change
TSH	9.2 µIU/mL	4.03 µIU/mL	−56%
Free T4	0.53 ng/dL	0.82 ng/dL	+55%
ESR	22 mm/hr	7 mm/hr	−68%
Triglycerides	172.7 mg/dL	104 mg/dL	−40%
ApoB	140 mg/dL	94 mg/dL	−33%
Homocysteine	9.01 µmol/L	6.1 µmol/L	−32%
Fasting insulin	13.46 µIU/mL	8.45 µIU/mL	−37%

At week 4: TSH 6.64 µIU/mL, fasting insulin 6.44 µIU/mL, with marked improvement in energy already reported.

Subjective Progress

Marked improvement in energy within approximately four weeks
Progression from near bed-bound to regular movement, gym participation and sustained daily activity
Resolution of binge-eating behavior
Improved bowel regularity by approximately eight weeks

What Changed Next

Thyroid markers improved when the physiological environment around the thyroid improved. That does not make hormone replacement unnecessary. It makes systemic assessment necessary. Iron deficiency persisted and required later targeted management, and sleep disruption remained an active treatment target.

Limitations

Documented Limitations

Cannot establish causality or attribute changes to any specific intervention. Multiple components ran simultaneously.
Single patient, no comparator or control group, short observation period with no long-term follow-up.
Did not control for assay variability or pre-analytical differences.
No repeat thyroid-antibody testing, so autoimmune resolution cannot be claimed.
Does not establish sustained euthyroidism or avoidance of future medication need.

Central Message

This case should not be read as evidence that autoimmune hypothyroidism is a lifestyle disorder, or as support for postponing levothyroxine in a newly diagnosed patient. It is a record of what closely supervised systemic repair moved, on a clear clock, with a clear threshold to prescribe.